Longitudinal associations of ALSFRS-R total score and plasma creatinine levels with mortality during follow-up
| No. of patients (%) | ALSFRS-R total score | Plasma creatinine | |||||
| HR | 95% CI | p Value* | HR | 95% CI | p Value* | ||
| Overall | 1241 (100) | 0.88 | 0.86 to 0.90 | p<0.001 | 0.93 | 0.91 to 0.94 | p<0.001 |
| Gender | p=0.09 | p=0.005 | |||||
| Male | 793 (64) | 0.88 | 0.86 to 0.91 | 0.93 | 0.91 to 0.95 | ||
| Female | 448 (36) | 0.84 to 0.89 | 0.90 | 0.88 to 0.93 | |||
| Site of onset | p=0.21 | p=0.93 | |||||
| Bulbar | 290 (23) | 0.87 | 0.84 to 0.89 | 0.93 | 0.91 to 0.94 | ||
| Other | 951 (77) | 0.88 | 0.86 to 0.91 | 0.93 | 0.91 to 0.94 | ||
*p Values are based on the likelihood ratio test (shared parameter models), adjusted for age, gender, baseline level plasma creatinine, baseline vital capacity and ΔFRS. Participants were followed for a maximum of 31.9 months (median 14.0 months).
ALSFRS-R, amyotrophic lateral sclerosis functional rating scale–revised.